1. Dose Selection of Antithrombin (Recombinant) for a Phase 3 Trial in Early-Onset Preeclampsia [149]. (May 2015) Authors: Paidas, Michael John; Frieling, Johan; de Jongh, Joost; Drenth, Henk-Jan; Streisand, James Journal: Obstetrics and gynecology Issue: Volume 125(2015)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Exploring the Role of Antithrombin Replacement for the Treatment of Preeclampsia: A Prospective Randomized Evaluation of the Safety and Efficacy of Recombinant Antithrombin in Very Preterm Preeclampsia (PRESERVE‐1). (27th February 2013) Authors: Paidas, Michael J.; Sibai, Bahaeddine M.; Triche, Elizabeth W.; Frieling, Johan; Lowry, Simon Journal: American journal of reproductive immunology Issue: Volume 69:Number 6(2013:Jun.) Page Start: 539 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Pharmacokinetics of Recombinant Human Antithrombin in Delivery and Surgery Patients With Hereditary Antithrombin Deficiency. (May 2014) Authors: DeJongh, Joost; Frieling, Johan; Lowry, Simon; Drenth, Henk-Jan Journal: Clinical and applied thrombosis/hemostasis Issue: Volume 20:Number 4(2014:May) Page Start: 355 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗